Valganciclovir入医保了吗？

Valganciclovir Hydrochloride Tablets (Valganciclovir Hydrochloride) is a prescription antiviral drug. In adults, Valganciclovir is used to treat cytomegalovirus (CMV) retinitis in people with immunodeficiency syndrome (AIDS). When the CMV virus infects the eye, it is called CMV retinitis. If CMV retinitis is not treated, blindness may result. To prevent CMV disease in people who have received a kidney, heart, or kidney-pancreas transplant and are at high risk for CMV disease. In Children, Valganciclovir Hydrochloride Tablets or Oral Solution: To prevent CMV disease in children 4 months to 16 years who have received a kidney transplant and are at high risk for CMV disease. To prevent CMV disease in children 1 month to 16 years of age who have received a heart transplant and are at high risk for CMV disease.

Cytomegalovirus infection is a common complication after organ transplantation, with an incidence rate as high as 50%. The pain caused by organ rejection, cardiovascular disease, post-transplantation diabetes and related treatments has seriously affected the quality of life of patients. Valganciclovir Hydrochloride Tablets (Valganciclovir) is an oral anti-cytomegalovirus infection drug that combines the advantages of oral administration and intravenous injection. Just taking 2 tablets of Valganciclovir Hydrochloride Tablets (Valganciclovir) every day can effectively prevent and treat CMV infection, avoid the direct and indirect harm caused by CMV infection, and significantly improve the patient's quality of life and long-term survival rate. 

In August 2006, Valganciclovir Hydrochloride Tablets (Valganciclovir) were launched in China with a specification of 450mg*60 tablets/box and a price of $16,500/box. Since it is an imported original drug and has a small audience, Valganciclovir Hydrochloride Tablets (Valganciclovir Hydrochloride) are not included in medical insurance.